How a medicine makes dangerous artery plaques safer
Atorvastatin Improves Plaque Stability in ApoE-Knockout Mice by Regulating Chemokines and Chemokine Receptors
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Atorvastatin didn’t lower cholesterol or shrink plaque size—but still cut vulnerable plaques by over 40%.
For decades, doctors taught that lowering LDL = less heart disease. This shows plaque stability can be improved without touching cholesterol levels.
Practical Takeaways
If you’re on statins, know you’re not just lowering cholesterol—you’re making your plaques safer. Don’t stop just because your LDL is 'normal'.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Atorvastatin didn’t lower cholesterol or shrink plaque size—but still cut vulnerable plaques by over 40%.
For decades, doctors taught that lowering LDL = less heart disease. This shows plaque stability can be improved without touching cholesterol levels.
Practical Takeaways
If you’re on statins, know you’re not just lowering cholesterol—you’re making your plaques safer. Don’t stop just because your LDL is 'normal'.
Publication
Journal
PLoS ONE
Year
2014
Authors
P. Nie, Dan-dan Li, Liu-Hua Hu, Shu-xuan Jin, Yingxue Yu, Zhaohua Cai, Qin Shao, Jieyan Shen, J. Yi, Hua Xiao, Linghong Shen, Ben He
Related Content
Claims (6)
Statins do not induce significant regression of established atherosclerotic plaque but reduce plaque progression and enhance plaque stability by lowering LDL cholesterol exposure to arterial walls.
In mice prone to clogged arteries, a daily dose of atorvastatin made the dangerous, rupture-prone plaques much less common—even though the overall blockage didn’t get smaller.
The drug lowered levels of two key inflammation signals in the blood, showing it reduces body-wide inflammation even when cholesterol doesn’t change.
The drug reduced the number of inflammatory immune cells inside the artery plaques by nearly 40%, which also made the plaques less fatty and changed their collagen structure.
The drug lowered the levels of chemical signals (MCP-1 and CX3CL1) that attract immune cells to plaques, and also reduced the number of receptors on blood cells that respond to those signals.